Leveraging Predictive Biomarkers for Targeted Therapies in NSCLC

Download these expert-selected slides to learn strategies in using biomarkers to guide treatment decisions for your patients with NSCLC.
Matthew Gubens, MD, MS
Format: Microsoft PowerPoint (.ppt)
File Size: 2.95 MB
Released: April 27, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Amgen
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

Video of expert discussion of emerging antibody-drug conjugates targeting HER2, HER3, and TROP2 for lung cancers from Clinical Care Options (CCO)

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
person default Conor Ernst Steuer, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.25 Medical Knowledge MOC point(s) Released: May 7, 2021 Expired: May 6, 2022

Downloadable slides highlighting strategies for assessing and using biomarkers to guide treatment for patients with NSCLC, by Clinical Care Options.

Matthew Gubens, MD, MS Lauren L. Ritterhouse, MD Released: May 7, 2021

Downloadable slides highlighting best approaches for detecting biomarkers to guide treatment decisions in NSCLC, by Clinical Care Options.

Lauren L. Ritterhouse, MD Released: April 27, 2021

On-demand webcast with experts’ review of the latest clinical trial data for antibody-drug conjugates in NSCLC, from Clinical Care Options (CCO)

Egbert F. Smit, MD, PhD
Program Director
David Planchard, MD, PhD Helena A. Yu, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 23, 2021 Expired: April 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue